by Fecal calprotectin is a protein found in the granulocytes of the immune system. Its presence in stool is an indicator of inflammation in the gastrointestinal tract, particularly the colon. Fecal calprotectin tests help in noninvasive, quantitative assessment of gut inflammation and are widely used in the diagnosis and management of gastrointestinal diseases such as inflammatory bowel disease (IBD). Rising incidence of gastrointestinal diseases globally are driving the demand for reliable and affordable diagnostic tests. Fecal calprotectin has proven to be highly effective in differentiating between inflammatory bowel disease from irritable bowel syndrome. The global fecal calprotectin test market is estimated to be valued at US$ 140.6 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: One of the key trends in the fecal calprotectin test market is the development and commercialization of rapid home-use test kits. Traditional laboratory testing involves sample collection by healthcare professionals and results take at least 24 hours. However, newer rapid home test kits provide qualitative on-site results within 15 minutes, enabling self-monitoring and timely disease management. This empowers patients and supports self-care, especially during periods of remission. Rapid home tests are also more cost-effective compared to laboratory testing and help address issues of test accessibility in remote locations. Their increasing availability is expected to boost market growth over the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the market requires high capital investment for R&D and compliance with stringent regulations. However, growing market opportunities and advancements in technologies are attracting new players.
Bargaining power of buyers: The bargaining power of buyers is high due to the availability of alternative diagnostic tests in the market. Buyers can negotiate on price and demand advanced features from existing players.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as established players have strong relationships with suppliers of raw materials and sample collection products. However, the threat of forward integration by suppliers exists.
Threat of new substitutes: The threat of new substitutes is moderate as alternative non-invasive diagnostic tests are available. However, fecal calprotectin tests have benefits of being affordable, safe, and effective that reduce the threat from substitutes.
Competitive rivalry: The competitive rivalry in the market is high among the top players due to their strong global presence and focus on expanding their product portfolios through strategic collaborations and new product launches.
Key Takeaways
The global Fecal Calprotectin Test Market Growth is expected to witness high over the forecast period.
Regional analysis: North America holds the largest share in the market owing to increasing research activities and growing awareness regarding fecal calprotectin tests in this region. Asia Pacific region is expected to witness fastest growth due to rising healthcare spending and increasing patient pool in developing countries like India and China.
Key players: Key players operating in the Fecal Calprotectin Test Market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., ALPCO. Companies are focused on introducing innovative products and entering partnerships to strengthen their geographic presence. For instance, Abbexa Limited launched a fecal calprotectin ELISA test kit with enhanced specificity and sensitivity.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
